Dystrophin isoform deficiency and upper-limb and respiratory function in Duchenne muscular dystrophy.
Chesshyre M. et al, (2025), Dev Med Child Neurol
X-linked myotubular myopathy: an untreated treatable disease.
Martin C. and Servais L., (2025), Expert Opin Biol Ther, 1 - 16
Spinal muscular atrophy in the UK: the human toll of slow decisions.
Servais L. et al, (2025), Lancet, 405, 619 - 620
Biological biomarkers in muscle diseases relevant for follow-up and evaluation of treatment.
Stemmerik MG. et al, (2025), Brain, 148, 363 - 375
Wearable sensors in paediatric neurology.
González Barral C. and Servais L., (2025), Dev Med Child Neurol
Population-based, first-tier genomic newborn screening in the maternity ward.
Boemer F. et al, (2025), Nat Med
Pushing the boundaries: future directions in the management of spinal muscular atrophy.
Moultrie F. et al, (2025), Trends Mol Med
LAP1 Interactome Profiling Provides New Insights into LAP1's Physiological Functions.
Pereira CD. et al, (2024), Int J Mol Sci, 25
Treatment strategies for patients with spinal muscular atrophy.
De Waele L. and Servais L., (2024), Expert Rev Neurother, 1 - 3
Gene therapy for spinal muscular atrophy: timing is key.
Servais L., (2024), Lancet Reg Health Eur, 47
Spinal muscular atrophy in Brazil: from individual treatment to global management.
Servais L. and Moreno CAM., (2024), J Pediatr (Rio J)
Newborn screening programs for spinal muscular atrophy worldwide in 2023.
Vrščaj E. et al, (2024), J Neuromuscul Dis, 11, 1180 - 1189
Cerebellar dysfunction in the mdx mouse model of Duchenne muscular dystrophy: An electrophysiological and behavioural study.
Prigogine C. et al, (2024), Eur J Neurosci
Early diagnosis of Duchenne muscular dystrophy - A Treat-NMD international workshop.
Lorentzos M. et al, (2024), Neuromuscul Disord, 45
Why should a 5q spinal muscular atrophy neonatal screening program be started?
Becker MM. et al, (2024), Arquivos de neuro-psiquiatria, 82, 1 - 9
Quantitative proteome analysis of LAP1-deficient human fibroblasts: A pilot approach for predicting the signaling pathways deregulated in LAP1-associated diseases
Pereira CD. et al, (2024), Biochemistry and Biophysics Reports, 39
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.
Servais L. et al, (2024), International journal of molecular sciences, 25
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.
Mackels L. et al, (2024), International journal of molecular sciences, 25